- WWJ Radio Tech Tour Spotlights Vestaron [Friday 03 May 2013, 21:09]
- BBC Radio Interviews Vestaron CEO [Tuesday 05 March 2013, 19:07]
- Vestaron Raises $10.2 Million From Series B Preferred Stock Financing [Tuesday 08 May 2012, 05:05]
- Vestaron Corporation Announces Filing of Insect Control Patents [Thursday 15 March 2012, 05:05]
- Vestaron Corporation Promotes Robert Kennedy to Chief Scientific Officer [Monday 23 January 2012, 05:05]
Written by Administrator
Monday, 23 January 2012 00:00
January 23, 2012 06:00 ET
Vestaron Corporation Promotes Robert Kennedy to Chief Scientific Officer
KALAMAZOO, MI--(Marketwire - Jan 23, 2012) - Vestaron Corporation today announced the promotion of Robert M. Kennedy, Ph.D. to the newly created position of Chief Scientific Officer. In this position, Dr. Kennedy will have overall scientific leadership responsibilities for the research and discovery of new peptide and synthetic leads for development of insect control products in the crop protection, public health and animal health markets. In so doing, Dr. Kennedy will continue to report to Steven Hartmeier, President and CEO.
Dr. Kennedy has served as Vice President of Research at Vestaron for the past three years, and has led the team to an anticipated registration filing with the EPA of its first product at the end of this first quarter. Dr. Kennedy's prior experience includes scientific leadership positions at Pfizer, Parke-Davis, American Cyanamid and an academic appointment at Columbia University. Dr. Kennedy also currently serves as an adjunct Associate Professor in the School of Pharmacy at the University of Michigan.
"Vestaron is the leader in the of development of venom peptides for biorational insect control," said Dr. Kennedy. "I am excited about the progress of our peptide product development programs and also our grant for the development of synthetic insecticides for the control of malarial vectors through the Foundation for the National Institutes of Health. I look forward to working with my colleagues to continue to advance our technology platform and contribute to the success of the company."
"Over the past several years, Dr. Kennedy has provided outstanding scientific leadership to the technical team across the company's GMO, peptide and synthetic product development streams. He has assumed broad responsibilities in our company, with a strong track record of success. He is a well-respected scientific leader in whom I have great confidence, and therefore I am pleased to announce this expansion of his role at Vestaron," noted CEO Steven Hartmeier.
Vestaron is developing a new generation of insecticides using natural peptides from spiders. Products under development have a unique mode of action, are highly effective against insects and related pests and are harmless to non-target species, including humans. Target markets include agriculture, animal health and specialty non-crop uses such as household insects. Vestaron CleanTech products will be ideally suited for the environmentally conscious twenty-first century. For more information visit www.vestaron.com.
Certain statements in this announcement contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors.
President and Chief Executive Officer
Email: Email Contact
Phone: (269) 372-3108
|< Prev||Next >|